Cleveland Biolabs jumps as SEC filing for Cytocom merger deemed effective

Statera Biopharma

18/06/2021 13:18

** Shares of biopharma co  CBLI.O  jump ~9% to $5.28
premarket; among top pct gainers across U.S. exchanges
    ** Says registration statement to U.S. SEC regarding planned
merger with Cytocom Inc was declared effective on June 10
 urn:newsml:reuters.com:*:nPn6GXfywa
    ** Cytocom, a biopharma co in the area of immune-modulation,
in October agreed to buy CBLI in all-stock deal  urn:newsml:reuters.com:*:nL4N2HB2R4
    ** The registration statement includes a definitive proxy
statement and a prospectus
    ** A meeting of CBLI's stockholders to approve the proposals
related to the merger will be held virtually on July 6
    ** Expects deal to close in Q3 
    ** Stock up 40.6% YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))